Eric Schadt on Truly Precise Medicine and AI in Pharma and Healthcare

By Bio-IT World Staff

October 14, 2026 | Precision medicine may be marketed as better diagnostics, but the bigger promise is better decisions at the bedside. In this conversation, computational biologist Eric Schadt explains why he has spent decades arguing that disease is a network property, not a single-gene story, and why the real goal is combining large-scale biomedical data with predictive modeling that actually changes patient outcomes. The goal is not more dashboards or prettier lab reports. The goal is individualized trajectories and treatment predictions that help clinicians move beyond population averages, especially for people poorly served by one-size-fits-all guidelines.

With Trends from the Trenches host Eleanor Howe, Schadt explores what an AI-native R&D organization looks like in practice. Instead of scattered tools and one-off pilots, Schadt describes small, integrated teams where AI engineers, AI scientists, and domain experts work as a unit, using scaled infrastructure and modern deep learning to compress what used to take dozens of people. The core idea is harmonization: not “a tool for writing” and “a tool for searching,” but an operating model where foundation models, agents, and workflows reinforce each other. Done well, it speeds discovery, improves decision quality, and makes room for deeper accountability rather than less.

The discussion then turns to a stealth effort aimed at bringing AI in healthcare closer to the patient and provider interface: clinical decision support that evolves into evidence-building and eventually influences standards of care. The technical emphasis is important: reasoning-focused large language models can orchestrate complex pipelines across multimodal foundation models that read clinical text, genomics, transcriptomics, and pathology images. Just as crucial, the system has to produce mechanistically interpretable, auditable traces so a physician can understand why a prediction is made, when it is safe to deviate from a guideline, and how to track outcomes over time.

Why is this so hard to deploy today? Schadt argues that advanced companion diagnostics and algorithm-informed, multi-feature tests face a punishing combination of regulatory burden, unclear reimbursement, and misaligned financial incentives. Payers often apply inconsistent evidence standards, leaving companies to shoulder massive risk without knowing if coverage will follow. Pharma economics can also discourage biomarker-driven stratification because smaller subpopulations may not produce blockbuster revenue, even if they produce better care. The result is slower adoption of precision medicine, fewer treatment-predictive tests, and more patients stuck with suboptimal standard of care.

Finally, the episode highlights patient agency and the coming shift in behavior. People already use AI to interpret medical records and question clinical opinions, and consumer health companies have proven demand by selling “routine” lab panels directly to patients. That willingness to pay out of pocket signals a hunger for clarity, context, and trustworthy guidance. The opportunity now is to pair that demand with credible, science-grounded AI systems, plus lab-in-the-loop automation and physical AI that can accelerate experimentation. If the ecosystem aligns policy, incentives, and trust, AI-driven personalized care can become less of a slogan and more of a lived reality.

Listen to the full conversation in the most recent episode of the Trends from the Trenches Podcast.